NO328147B1 - Semi-syntetiske ecteinascidiner - Google Patents
Semi-syntetiske ecteinascidiner Download PDFInfo
- Publication number
- NO328147B1 NO328147B1 NO20004978A NO20004978A NO328147B1 NO 328147 B1 NO328147 B1 NO 328147B1 NO 20004978 A NO20004978 A NO 20004978A NO 20004978 A NO20004978 A NO 20004978A NO 328147 B1 NO328147 B1 NO 328147B1
- Authority
- NO
- Norway
- Prior art keywords
- semi
- compound
- mmol
- iso
- equiv
- Prior art date
Links
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract description 14
- 230000000704 physical effect Effects 0.000 abstract 1
- 229960000977 trabectedin Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 241000798369 Ecteinascidia turbinata Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 240000002044 Rhizophora apiculata Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8080298P | 1998-04-06 | 1998-04-06 | |
PCT/US1999/007471 WO1999051238A1 (en) | 1998-04-06 | 1999-04-05 | Semi-synthetic ecteinascidins |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20004978D0 NO20004978D0 (no) | 2000-10-03 |
NO20004978L NO20004978L (no) | 2000-12-05 |
NO328147B1 true NO328147B1 (no) | 2009-12-21 |
Family
ID=22159716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20004978A NO328147B1 (no) | 1998-04-06 | 2000-10-03 | Semi-syntetiske ecteinascidiner |
Country Status (28)
Country | Link |
---|---|
US (1) | US6124293A (ja) |
EP (2) | EP1876180A3 (ja) |
JP (1) | JP4443043B2 (ja) |
KR (1) | KR100603219B1 (ja) |
CN (1) | CN1157189C (ja) |
AT (1) | ATE370148T1 (ja) |
AU (1) | AU758100B2 (ja) |
BG (1) | BG65088B1 (ja) |
BR (1) | BR9909488B1 (ja) |
CA (1) | CA2327468C (ja) |
CY (1) | CY1106988T1 (ja) |
CZ (1) | CZ301083B6 (ja) |
DE (1) | DE69936845T2 (ja) |
DK (1) | DK1067933T3 (ja) |
ES (1) | ES2292237T3 (ja) |
HK (1) | HK1033651A1 (ja) |
HU (1) | HUP0104273A3 (ja) |
IL (2) | IL138856A0 (ja) |
MX (1) | MXPA00009840A (ja) |
NO (1) | NO328147B1 (ja) |
NZ (1) | NZ507350A (ja) |
PL (1) | PL196809B1 (ja) |
PT (1) | PT1067933E (ja) |
RU (1) | RU2217432C2 (ja) |
SK (1) | SK285669B6 (ja) |
TR (1) | TR200002921T2 (ja) |
UA (1) | UA59439C2 (ja) |
WO (1) | WO1999051238A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
WO1999058125A1 (en) * | 1998-05-11 | 1999-11-18 | Pharma Mar, S.A. | Metabolites of ecteinascidin 743 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
AR035842A1 (es) | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
US6686470B2 (en) | 2000-01-19 | 2004-02-03 | The Trustees Of Columbia University In The City Of New York | Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
US7919493B2 (en) * | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
AU2002239565B2 (en) * | 2000-11-03 | 2007-11-15 | President And Fellows Of Harvard College | Saframycins, analogues and uses thereof |
JP4391083B2 (ja) * | 2000-11-06 | 2009-12-24 | ファルマ・マール・ソシエダード・アノニマ | 効果的な抗腫瘍治療 |
GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0119243D0 (en) | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
EP1689404B9 (en) * | 2003-11-13 | 2009-04-22 | Pharma Mar, S.A.U. | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
NZ552607A (en) * | 2004-07-09 | 2009-07-31 | Pharma Mar Sa | Prognostic molecular markers |
US20080242670A2 (en) * | 2004-09-29 | 2008-10-02 | Pharma Mar S.A., Sociedad Unipersonal | Anti-Inflammatory Agents |
CN101119750B (zh) * | 2004-10-26 | 2013-03-06 | 法马马私人股份有限公司 | 抗癌治疗 |
BRPI0517238B1 (pt) | 2004-10-29 | 2021-11-09 | Pharma Mar, S.A. | Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução |
GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
CN100355775C (zh) * | 2006-01-20 | 2007-12-19 | 南方医科大学 | 一种海鞘多肽及其制备方法 |
WO2009050303A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for et-743 treatment |
AU2011328004C1 (en) | 2010-11-12 | 2017-01-19 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
EP3412293A4 (en) * | 2016-02-04 | 2019-10-16 | Jiangsu Hengrui Medicine Co., Ltd. | INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING TRABECTEDINE FOR EXTERNAL USE AT THE GASTROINTESTINAL LEVEL, AND METHOD OF MANUFACTURING THE SAME |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
US5440055A (en) * | 1993-03-12 | 1995-08-08 | Aphios Corporation | Method and apparatus for extracting taxol from source materials |
US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
-
1999
- 1999-04-05 DE DE69936845T patent/DE69936845T2/de not_active Expired - Lifetime
- 1999-04-05 CN CNB998070769A patent/CN1157189C/zh not_active Expired - Fee Related
- 1999-04-05 BR BRPI9909488-6A patent/BR9909488B1/pt not_active IP Right Cessation
- 1999-04-05 NZ NZ507350A patent/NZ507350A/xx unknown
- 1999-04-05 EP EP07011035A patent/EP1876180A3/en not_active Withdrawn
- 1999-04-05 HU HU0104273A patent/HUP0104273A3/hu unknown
- 1999-04-05 US US09/286,242 patent/US6124293A/en not_active Expired - Fee Related
- 1999-04-05 JP JP2000542009A patent/JP4443043B2/ja not_active Expired - Fee Related
- 1999-04-05 AU AU34713/99A patent/AU758100B2/en not_active Ceased
- 1999-04-05 ES ES99916379T patent/ES2292237T3/es not_active Expired - Lifetime
- 1999-04-05 CA CA002327468A patent/CA2327468C/en not_active Expired - Fee Related
- 1999-04-05 KR KR1020007011112A patent/KR100603219B1/ko not_active IP Right Cessation
- 1999-04-05 SK SK1501-2000A patent/SK285669B6/sk not_active IP Right Cessation
- 1999-04-05 MX MXPA00009840A patent/MXPA00009840A/es active IP Right Grant
- 1999-04-05 DK DK99916379T patent/DK1067933T3/da active
- 1999-04-05 IL IL13885699A patent/IL138856A0/xx active IP Right Grant
- 1999-04-05 AT AT99916379T patent/ATE370148T1/de not_active IP Right Cessation
- 1999-04-05 EP EP99916379A patent/EP1067933B1/en not_active Expired - Lifetime
- 1999-04-05 PT PT99916379T patent/PT1067933E/pt unknown
- 1999-04-05 CZ CZ20003650A patent/CZ301083B6/cs not_active IP Right Cessation
- 1999-04-05 PL PL343439A patent/PL196809B1/pl not_active IP Right Cessation
- 1999-04-05 WO PCT/US1999/007471 patent/WO1999051238A1/en active IP Right Grant
- 1999-04-05 TR TR2000/02921T patent/TR200002921T2/xx unknown
- 1999-04-05 RU RU2000128058/04A patent/RU2217432C2/ru not_active IP Right Cessation
- 1999-05-04 UA UA2000105674A patent/UA59439C2/uk unknown
-
2000
- 2000-10-03 NO NO20004978A patent/NO328147B1/no not_active IP Right Cessation
- 2000-10-04 IL IL138856A patent/IL138856A/en not_active IP Right Cessation
- 2000-11-02 BG BG104902A patent/BG65088B1/bg unknown
-
2001
- 2001-06-19 HK HK01104227A patent/HK1033651A1/xx not_active IP Right Cessation
-
2007
- 2007-11-08 CY CY20071101439T patent/CY1106988T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO328147B1 (no) | Semi-syntetiske ecteinascidiner | |
US20080234279A1 (en) | Ecteinascidins | |
EP0670314A1 (en) | Farnesyltransferase inhibitor | |
HU177154B (en) | New process for preparing dimeric vinca alkaloids | |
EP3077402B1 (en) | Anticancer maytansinoids with two fused macrocyclic rings | |
US6087369A (en) | Indole derivatives, process for producing the same and medicinal uses of the same | |
EA014689B1 (ru) | Новые соединения - аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат | |
NZ241023A (en) | Condensed benzazepine derivatives and pharmaceutical compositions | |
CA2225807C (en) | Use of lamellarin-class alkaloids in methods of treatment | |
ZA200407611B (en) | Hemiasterlin derivatives and uses thereof in the treatment of cancer | |
CA2205872A1 (en) | Acrylamide derivatives and process for production thereof | |
KR101496374B1 (ko) | 항종양 활성을 갖는 캄프토테신 유도체 | |
KR20080075911A (ko) | 항종양 화합물 | |
KR101174112B1 (ko) | 종양 억제 활성을 갖는 캄토테신의 7-이미노 유도체 | |
KR20030069993A (ko) | 트리아졸로-에포틸론 | |
DE60209029T2 (de) | Polycyclische verbindungen mit antitumor-wirkung | |
FI66607B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-5,6-dianhydro-hexitoler | |
EA005200B1 (ru) | Новые соединения карбамат и тиокарбамат подофиллотоксина, способ их получения и содержащие их фармацевтические композиции | |
US5248692A (en) | DC-89 derivatives as anti-tumor agents | |
JP4282323B2 (ja) | ストレプトグラミン誘導体、その製造およびそれを含有する組成物 | |
CN111377854A (zh) | Cxcr4抑制剂及其应用 | |
WO2015158306A1 (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
JPH08208653A (ja) | アクリルアミド誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |